L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression

Biochemical Pharmacology

Volumn 85, Issue 7, 2013, Pages 937-944

  Zambrano, Sonia ^a   Blanca, Antonio J ^a   Ruiz Armenta, María V ^a   Miguel Carrasco, José L ^a   Arévalo, Miguel ^b   Vázquez, María J ^a   Mate, Alfonso ^a   Vázquez, Carmen M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Fibrosis; Heart; Hypertension; l Carnitine; l NAME; PPAR

Indexed keywords

CARNITINE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; N(G) NITROARGININE METHYL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOWN REGULATION; HEART MUSCLE FIBROSIS; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARNITINE; COLLAGEN TYPE I; COLLAGEN TYPE II; CONNECTIVE TISSUE GROWTH FACTOR; FIBROSIS; HYPERTENSION; MALE; MEMBRANE GLYCOPROTEINS; MYOCARDIUM; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; PPAR GAMMA; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84874666148     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.12.021     Document Type: Article

References (48)

1. Ciulla MM, Paliotti R, Carini M, Aldini G. Fibrosis, enzymatic and non-enzymatic cross-links in hypertensive heart disease. Cardiovasc Hematol Disord Drug Targets, in press.
2. A.U. Shahbaz, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, I.C. Gerling, and J.E. McGee Fibrosis in hypertensive heart disease: molecular pathways and cardioprotective strategies J Hypertens 28 Suppl. 1 2010 S25 S32
3. C. Hu, A. Dandapat, L. Sun, J.A. Khan, Y. Liu, and P.L. Hermonat Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts J Biol Chem 283 2008 10226 10231
4. Y. Alvarez, A.M. Briones, R. Hernanz, J.V. Perez-Giron, M.J. Alonso, and M. Salaices Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats Br J Pharmacol 153 2008 926 935 (Pubitemid 351328931)
5. N. Hermida, B. Lopez, A. Gonzalez, J. Dotor, J.J. Lasarte, and P. Sarobe A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats Cardiovasc Res 81 2009 601 609
6. J.L. Mehta, and H. Attramadal The TGFbeta superfamily in cardiovascular biology Cardiovasc Res 74 2007 181 183
7. A. Leask Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation Circ Res 106 2010 1675 1680
8. A. Daniels, M. van Bilsen, R. Goldschmeding, G.J. van der Vusse, and F.A. van Nieuwenhoven Connective tissue growth factor and cardiac fibrosis Acta Physiol (Oxf) 195 2009 321 338
9. F. Kuwahara, H. Kai, K. Tokuda, M. Kai, A. Takeshita, and K. Egashira Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats Circulation 106 2002 130 135 (Pubitemid 34747453)
10. D. Pohlers, J. Brenmoehl, I. Loffler, C.K. Muller, C. Leipner, and S. Schultze-Mosgau TGF-beta and fibrosis in different organs-molecular pathway imprints Biochim Biophys Acta 1792 2009 746 756
11. M. Bujak, and N.G. Frangogiannis The role of TGF-beta signaling in myocardial infarction and cardiac remodeling Cardiovasc Res 74 2007 184 195 (Pubitemid 46517504)
12. W.S. Choi, A. Mitsumoto, and I.E. Kochevar Involvement of reactive oxygen species in TGF-beta1-induced tropoelastin expression by human dermal fibroblasts Photochem Photobiol 85 2009 1425 1433
13. A. Djamali, A. Vidyasagar, M. Adulla, D. Hullett, and S. Reese Nox-2 is a modulator of fibrogenesis in kidney allografts Am J Transplant 9 2009 74 82
14. A. Sugawara, A. Uruno, M. Kudo, K. Matsuda, C.W. Yang, and S. Ito Effects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease Endocr J 57 2010 847 852
15. Q.N. Diep, F. Amiri, R.M. Touyz, J.S. Cohn, D. Endemann, and M.F. Neves PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation Hypertension 40 2002 866 871 (Pubitemid 35434908)
16. R.E. Routh, J.H. Johnson, and K.J. McCarthy Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro Kidney Int 61 2002 1365 1376 (Pubitemid 34304497)
17. T. Kawai, T. Masaki, S. Doi, T. Arakawa, Y. Yokoyama, and T. Doi PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta Lab Invest 89 2009 47 58
18. A. Mate, J.L. Miguel-Carrasco, and C.M. Vazquez The therapeutic prospects of using l-carnitine to manage hypertension-related organ damage Drug Discov Today 15 2010 484 492
19. A. Mate, J.L. Miguel-Carrasco, M.T. Monserrat, and C.M. Vazquez Systemic antioxidant properties of l-carnitine in two different models of arterial hypertension J Physiol Biochem 66 2010 127 136
20. J.L. Miguel-Carrasco, A. Mate, M.T. Monserrat, J.L. Arias, O. Aramburu, and C.M. Vazquez The role of inflammatory markers in the cardioprotective effect of l-carnitine in l-NAME-induced hypertension Am J Hypertens 21 2008 1231 1237
21. J.L. Miguel-Carrasco, M.T. Monserrat, A. Mate, and C.M. Vazquez Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats Eur J Pharmacol 632 2010 65 72
22. P. Chomczynski, and N. Sacchi Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 162 1987 156 159 (Pubitemid 17064313)
23. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402 408 (Pubitemid 34164012)
24. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 1976 248 254
25. Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco JL, Revilla E, Santa-Maria C, et al. The renoprotective effect of l-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression. Eur J Nutr (2012), http://dx.doi.org/10.1007/s00394-012-0470-x.
26. A.M. Rodriguez-Lopez, O. Flores, M.A. Arevalo, and J.M. Lopez-Novoa Glomerular cell proliferation and apoptosis in uninephrectomized spontaneously hypertensive rats Kidney Int Suppl 68 1998 S36 S40
27. C. Farsang Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk Vasc Health Risk Manag 7 2011 605 622
28. W.C. Dornas, and M.E. Silva Animal models for the study of arterial hypertension J Biosci 36 2011 731 737
29. D. O'Brien, P. Chunduri, A. Iyer, and L. Brown l-Carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats Basic Clin Pharmacol Toxicol 106 2010 296 301
30. S. Vrankova, J. Parohova, A. Barta, P. Janega, F. Simko, and O. Pechanova Effect of nuclear factor kappa B inhibition on l-NAME-induced hypertension and cardiovascular remodelling J Hypertens 28 Suppl. 1 2010 S45 S49
31. Y. Omori, T. Ohtani, Y. Sakata, T. Mano, Y. Takeda, and S. Tamaki l-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease J Hypertens 30 2012 1834 1844
32. S. Jesmin, Y. Hattori, H. Togashi, K. Ueno, M. Yoshioka, and I. Sakuma Age-related changes in cardiac expression of VEGF and its angiogenic receptor KDR in stroke-prone spontaneously hypertensive rats Mol Cell Biochem 272 2005 63 73 (Pubitemid 40867366)
33. J.L. Miguel-Carrasco, A. Baltanas, C. Cebrian, M.U. Moreno, B. Lopez, and N. Hermida Blockade of TGF-beta 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats Oxid Med Cell Longev 2012 2012 726940
34. T. Takahashi, H. Ono, Y. Ono, T. Ishimitsu, and H. Matsuoka Combination therapy with telmisartan and spironolactone alleviates l-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1) Int Heart J 48 2007 637 647 (Pubitemid 350200186)
35. R.P. Brandes, I. Takac, and K. Schroder No superoxide - no stress?: Nox4, the good NADPH oxidase Arterioscler Thromb Vasc Biol 31 2011 1255 1257
36. N. Varo, J.C. Etayo, G. Zalba, J. Beaumont, M.J. Iraburu, and C. Montiel Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats J Hypertens 17 1999 107 114 (Pubitemid 29086195)
37. H. Ono, M. Saitoh, Y. Ono, T. Ishimitu, and H. Matsuoka Imidapril improves l-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats J Hypertens 22 2004 1389 1395 (Pubitemid 38888086)
38. J. Holtz Pathophysiology of heart failure and the renin-angiotensin- system Basic Res Cardiol 88 Suppl. 1 1993 183 201 (Pubitemid 23226447)
39. J.J. Schultz, S.A. Witt, B.J. Glascock, M.L. Nieman, P.J. Reiser, and S.L. Nix TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II J Clin Invest 109 2002 787 796 (Pubitemid 34263155)
40. S.E. Campbell, and L.C. Katwa Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts J Mol Cell Cardiol 29 1997 1947 1958 (Pubitemid 27303099)
41. M.M. Martin, J.A. Buckenberger, J. Jiang, G.E. Malana, D.L. Knoell, and D.S. Feldman TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways Am J Physiol Lung Cell Mol Physiol 293 2007 L790 L799
42. S.Z. Duan, C.Y. Ivashchenko, M.G. Usher, and R.M. Mortensen PPAR-gamma in the cardiovascular system PPAR Res 2008 2008 745804
43. S.J. Nicholls, and K. Uno Peroxisome proliferator-activated receptor (PPAR alpha/gamma) agonists as a potential target to reduce cardiovascular risk in diabetes Diab Vasc Dis Res 9 2012 89 94
44. L. Han, M. Li, Y. Liu, C. Han, and P. Ye Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats Pharmacology 89 2012 74 82
45. T.I. Lee, Y.H. Kao, Y.C. Chen, N.H. Pan, Y.K. Lin, and Y.J. Chen Cardiac peroxisome-proliferator-activated receptor expression in hypertension co-existing with diabetes Clin Sci (Lond) 121 2011 305 312
46. H.H. Chen, Y.M. Sue, C.H. Chen, Y.H. Hsu, C.C. Hou, and C.Y. Cheng Peroxisome proliferator-activated receptor alpha plays a crucial role in l-carnitine anti-apoptosis effect in renal tubular cells Nephrol Dial Transplant 24 2009 3042 3049
47. L. Gomez-Amores, A. Mate, J.L. Miguel-Carrasco, L. Jimenez, A. Jos, and A.M. Camean l-Carnitine attenuates oxidative stress in hypertensive rats J Nutr Biochem 18 2007 533 540 (Pubitemid 47043414)
48. P. Rajasekar, N. Palanisamy, and C.V. Anuradha Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by l-carnitine: a study in the fructose-fed hypertensive rat Clin Exp Hypertens 29 2007 517 530 (Pubitemid 350223251)